• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Topical immune modulation and risk of cancer].

作者信息

Deleuran Mette, Zachariae Claus, Thestrup-Pedersen Kristian

机构信息

Dermatologisk Afdeling S, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C.

出版信息

Ugeskr Laeger. 2009 Aug 24;171(35):2468-71.

PMID:19732533
Abstract

This article reviews if local immunosuppression of atopic dermatitis is associated with an increased risk of cancer - as implicated by a warning issued by the FDA and EMEA health authorities because systemic immunosuppression of transplanted patients leads to a significant increase of non-melanoma skin cancer and lymphoma. So far, no studies support that the use of topical immunosuppression increases the risk of local or systemic cancer.

摘要

相似文献

1
[Topical immune modulation and risk of cancer].
Ugeskr Laeger. 2009 Aug 24;171(35):2468-71.
2
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.特应性皮炎局部应用钙调磷酸酶抑制剂的恶性肿瘤担忧：事实与争议。
Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001.
3
Association between exposure to topical tacrolimus or pimecrolimus and cancers.局部使用他克莫司或吡美莫司与癌症的关联性。
Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.
4
Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.使用吡美莫司、他克莫司和中至高效糖皮质激素进行局部治疗与淋巴瘤风险
Dermatology. 2009;219(1):7-21. doi: 10.1159/000209289. Epub 2009 Mar 17.
5
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.湿疹药物他克莫司（普特彼）和吡美莫司（爱宁达）：癌症相关问题。
CMAJ. 2005 Apr 26;172(9):1179-80. doi: 10.1503/cmaj.050373. Epub 2005 Apr 7.
6
Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians.
Am J Clin Dermatol. 2007;8(4):189-94. doi: 10.2165/00128071-200708040-00001.
7
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.外用钙调神经磷酸酶抑制剂吡美莫司治疗特应性皮炎：安全性最新进展
Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62.
8
[Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ].[钙调神经磷酸酶抑制剂治疗特应性皮炎。局部用皮质类固醇现在仅用于严重发作期？]
MMW Fortschr Med. 2003 Jul 24;145(29-30):62.
9
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.美国过敏、哮喘与免疫学会以及美国过敏、哮喘与免疫学院外用钙调神经磷酸酶抑制剂特别工作组报告。
J Allergy Clin Immunol. 2005 Jun;115(6):1249-53. doi: 10.1016/j.jaci.2005.04.006.
10
Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.外用他克莫司治疗特应性皮炎患者的非黑色素瘤皮肤癌
J Dermatolog Treat. 2005 Aug;16(3):149-53. doi: 10.1080/09546630510041088.

引用本文的文献

1
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.已发表试验的系统评价：外用糖皮质激素和外用钙调神经磷酸酶抑制剂在儿童特应性皮炎患者中的长期安全性
BMC Pediatr. 2016 Jun 7;16:75. doi: 10.1186/s12887-016-0607-9.